{"id":"docetaxel-standard-dose-vitamin-d2","safety":{"commonSideEffects":[{"rate":"75–90","effect":"Neutropenia"},{"rate":"50–70","effect":"Anemia"},{"rate":"25–50","effect":"Thrombocytopenia"},{"rate":"20–40","effect":"Peripheral neuropathy"},{"rate":"40–60","effect":"Fatigue"},{"rate":"30–50","effect":"Nausea/vomiting"},{"rate":"50–75","effect":"Alopecia"},{"rate":"5–15","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL1536","moleculeType":"Small molecule","molecularWeight":"396.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Vitamin D2 (ergocalciferol) is added as a potential adjunctive agent to modulate immune response and possibly mitigate chemotherapy-related adverse effects, though the synergistic benefit in this combination requires clinical validation.","oneSentence":"Docetaxel stabilizes microtubules to inhibit cancer cell division, while vitamin D2 may enhance immune function and potentially reduce docetaxel toxicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:41.343Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under investigation in phase 3 trial at King Faisal Specialist Hospital & Research Center)"}]},"trialDetails":[{"nctId":"NCT00944424","phase":"PHASE3","title":"Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2009-07","conditions":"Breast Cancer","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Docetaxel + Standard dose Vitamin D2","genericName":"Docetaxel + Standard dose Vitamin D2","companyName":"King Faisal Specialist Hospital & Research Center","companyId":"king-faisal-specialist-hospital-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel stabilizes microtubules to inhibit cancer cell division, while vitamin D2 may enhance immune function and potentially reduce docetaxel toxicity. Used for Solid tumors (specific indication under investigation in phase 3 trial at King Faisal Specialist Hospital & Research Center).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}